Review

resmetirom (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress resmetirom

CS/CNA Exhibit Therapeutic Advantages in the Treatment of Non-Alcoholic Steatohepatitis (NASH). (A) Schematic illustration of the HFMCD-induced NASH model and oral administration schedule. Mice were fed an HFMCD diet for 8 weeks and orally administered vehicle, free CEL, <t>Resmetirom,</t> or CS/CNA during weeks 4–8; (B–E) Serum levels of ALT, AST, TG, and TC in different treatment groups; (F) Schematic illustration of the glucose tolerance test (GTT) and insulin tolerance test (ITT); (G, I) Blood glucose curves and corresponding area under the curve (AUC) analysis during GTT; (H, J) Blood glucose curves and corresponding AUC analysis during ITT; (K) Representative gross liver images and quantitative analysis of liver weight/body weight ratio. Scale bar: 1 cm; (L) Representative H&E-stained liver sections and NAS score analysis. Scale bar: 100 μm; (M) Representative Masson-stained liver sections and quantitative analysis of fibrotic area. Scale bar: 100 μm; (N) Representative Sirius Red-stained liver sections and quantitative analysis of Sirius Red-positive area. Scale bar: 250 μm; (O) Representative Oil Red O-stained liver sections and quantitative analysis of Oil Red O-positive area. Scale bar: 100 μm. Data are presented as mean ± SEM, n = 5. Statistical significance was analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Resmetirom, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/resmetirom/Resmetirom/pmc13333370-52-2-8
Average 95 stars, based on 33 article reviews

resmetirom - by Bioz Stars, 2026-10

95/100 stars

Images

1) Product Images from "Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis"

Article Title: Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis

Journal: Materials Today Bio

doi: 10.1016/j.mtbio.2026.103369

Figure Legend Snippet: CS/CNA Exhibit Therapeutic Advantages in the Treatment of Non-Alcoholic Steatohepatitis (NASH). (A) Schematic illustration of the HFMCD-induced NASH model and oral administration schedule. Mice were fed an HFMCD diet for 8 weeks and orally administered vehicle, free CEL, Resmetirom, or CS/CNA during weeks 4–8; (B–E) Serum levels of ALT, AST, TG, and TC in different treatment groups; (F) Schematic illustration of the glucose tolerance test (GTT) and insulin tolerance test (ITT); (G, I) Blood glucose curves and corresponding area under the curve (AUC) analysis during GTT; (H, J) Blood glucose curves and corresponding AUC analysis during ITT; (K) Representative gross liver images and quantitative analysis of liver weight/body weight ratio. Scale bar: 1 cm; (L) Representative H&E-stained liver sections and NAS score analysis. Scale bar: 100 μm; (M) Representative Masson-stained liver sections and quantitative analysis of fibrotic area. Scale bar: 100 μm; (N) Representative Sirius Red-stained liver sections and quantitative analysis of Sirius Red-positive area. Scale bar: 250 μm; (O) Representative Oil Red O-stained liver sections and quantitative analysis of Oil Red O-positive area. Scale bar: 100 μm. Data are presented as mean ± SEM, n = 5. Statistical significance was analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Techniques Used: Staining

Recombinant:

Article Title: A thioacrylamide-based compound directly counteracts hepatic fibrosis with profound anti-obesity action
Article Snippet: 12 13 2.2 Cell culture 14 The human hepatic stellate cell line, LX2 (#SCC064, Merck, Darmstadt, Germany), was cultivated 15 according to the manufacturer’s instructions. .. LX2 cells were starved for fetal bovine serum (FBS) and 16 pretreated with HK1 or HK3 (10 μM, Taros Chemicals, Dortmund, Germany), the corresponding DMSO 17 vehicle (Sigma-Aldrich, Munich, Germany) or competitor drugs semaglutide (10 μM), lanifibranor (10 18 μM; both Biomol GmbH, Hamburg, Germany) and resmetirom (10 μM; MedChemExpress, Monmouth 19 Junction, NJ, USA) prior to exposure with 5 ng/ml recombinant transforming growth factor-β1 (TGF-β1, 20 R&D Systems) for 24h. ..

other:

Article Title: Myricetin stabilizes PINK1 to activate mitophagy and ameliorate metabolic dysfunction-associated steatotic liver disease
Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

CMC:

Article Title: Cichoriin suppresses hepatic lipid accumulation and fibrosis in mice metabolic dysfunction associated steatohepatitis via the AMPK pathway.
Article Snippet: Previous studies highlight the critical role of AMP-activated protein kinase (AMPK) in hepatic lipid metabolism, yet natural activators for metabolic dysfunction-associated steatohepatitis (MASH) remain underexplored.. This study investigated whether cichoriin from Cichorium intybus mitigates MASH fibrosis.. C57BL/6J mice fed a Gubra-Amylin NASH diet for 20 weeks received cichoriin (100 or 200 mg/kg/day, oral gavage) for 6 weeks.

Positive Control:

Image Search Results

Journal: Materials Today Bio

Article Title: Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis

doi: 10.1016/j.mtbio.2026.103369

Figure Lengend Snippet: CS/CNA Exhibit Therapeutic Advantages in the Treatment of Non-Alcoholic Steatohepatitis (NASH). (A) Schematic illustration of the HFMCD-induced NASH model and oral administration schedule. Mice were fed an HFMCD diet for 8 weeks and orally administered vehicle, free CEL, Resmetirom, or CS/CNA during weeks 4–8; (B–E) Serum levels of ALT, AST, TG, and TC in different treatment groups; (F) Schematic illustration of the glucose tolerance test (GTT) and insulin tolerance test (ITT); (G, I) Blood glucose curves and corresponding area under the curve (AUC) analysis during GTT; (H, J) Blood glucose curves and corresponding AUC analysis during ITT; (K) Representative gross liver images and quantitative analysis of liver weight/body weight ratio. Scale bar: 1 cm; (L) Representative H&E-stained liver sections and NAS score analysis. Scale bar: 100 μm; (M) Representative Masson-stained liver sections and quantitative analysis of fibrotic area. Scale bar: 100 μm; (N) Representative Sirius Red-stained liver sections and quantitative analysis of Sirius Red-positive area. Scale bar: 250 μm; (O) Representative Oil Red O-stained liver sections and quantitative analysis of Oil Red O-positive area. Scale bar: 100 μm. Data are presented as mean ± SEM, n = 5. Statistical significance was analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Cy5-amine and resmetirom (purity ≥99.90%) was bought from MedChemExpress (Shanghai, China).

Techniques: Staining

HK1 and HK3 counteract upregulation of pro-fibrotic and inflammation-related proteins in LX2 cell model. LX2 cells were exposed to HK1 or HK3 (10 μM) prior to stimulation with TGF-β1 (5 ng/ml, 24 h) or the corresponding treatments alone. Relative protein levels of (A) FN1 and (B, C) COL1A1 were quantified by normalizing to the total protein amounts of vinculin, β-tubulin and GAPDH, respectively. (C) In addition, LX cells were exposed to semaglutide, lanifibranor and resmetirom (all 10 μM). mRNA levels of (D) ACTA2 , (E) EGR2 , and (F) SMAD4 were normalized to the endogenous control gene GAPDH . Secreted protein levels of (G) LIF and (H) VEGFA were measured by OLINK, and the fold change was calculated by conversion of NPX values to a linear scale (2 NPX ). Plasma concentrations of (I) IL-6 were determined by ELISA. Data are presented as the mean ± SEM; n = 3-5; one-way ANOVA with Tukey’s (A-D, G-I) or Dunnett’s post hoc test (E, F); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001 vs . corresponding vehicle normalized in control (A, B, D-F) or vs . untreated cells (C, G-I); # p < 0.05, ## p < 0.01, ### p < 0.001 vs . TGF-β1 alone. NPX, normalized protein expression.

Journal: JHEP Reports

Article Title: A thioacrylamide-based compound directly counteracts hepatic fibrosis with profound anti-obesity action

doi: 10.1016/j.jhepr.2026.101792

Figure Lengend Snippet: HK1 and HK3 counteract upregulation of pro-fibrotic and inflammation-related proteins in LX2 cell model. LX2 cells were exposed to HK1 or HK3 (10 μM) prior to stimulation with TGF-β1 (5 ng/ml, 24 h) or the corresponding treatments alone. Relative protein levels of (A) FN1 and (B, C) COL1A1 were quantified by normalizing to the total protein amounts of vinculin, β-tubulin and GAPDH, respectively. (C) In addition, LX cells were exposed to semaglutide, lanifibranor and resmetirom (all 10 μM). mRNA levels of (D) ACTA2 , (E) EGR2 , and (F) SMAD4 were normalized to the endogenous control gene GAPDH . Secreted protein levels of (G) LIF and (H) VEGFA were measured by OLINK, and the fold change was calculated by conversion of NPX values to a linear scale (2 NPX ). Plasma concentrations of (I) IL-6 were determined by ELISA. Data are presented as the mean ± SEM; n = 3-5; one-way ANOVA with Tukey’s (A-D, G-I) or Dunnett’s post hoc test (E, F); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001 vs . corresponding vehicle normalized in control (A, B, D-F) or vs . untreated cells (C, G-I); # p < 0.05, ## p < 0.01, ### p < 0.001 vs . TGF-β1 alone. NPX, normalized protein expression.

Article Snippet: Although numerous compounds are currently being tested in clinical trials, only two drugs, resmetirom (Rezdiffra; Madrigal Pharmaceuticals) and semaglutide (Wegovy; Novo Nordisk) have been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Techniques: Control, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Expressing